Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Monday 29 June 2026 (4)
  • Until platform closure (14)
Poster categories
  • Thematic Poster Session (18)
keywords
Session Reference
  • L-TPS01 (12)
  • L-TPS02 (14)
  • L-TPS03 (10)
  • L-TPS04 (13)
  • L-TPS05 (10)
  • L-TPS06 (8)
  • L-TPS07 (14)
  • L-TPS08 (9)
  • L-TPS09 (13)
  • L-TPS10 (14)
  • L-TPS11 (15)
  • L-TPS12 (11)
  • L-TPS13 (12)
  • L-TPS14 (14)
  • L-TPS15 (12)
  • L-TPS16 (9)
  • L-TPS17 (13)
  • L-TPS18 (13)
  • L-TPS19 (9)
  • L-TPS20 (14)
  • L-TPS21 (8)
  • L-TPS22 (10)
  • L-TPS23 (14)
  • L-TPS24 (14)
  • L-TPS25 (5)
  • TPS01 (14)
  • TPS02 (12)
  • TPS03 (10)
  • TPS04 (12)
  • TPS05 (13)
  • TPS06 (14)
  • TPS07 (9)
  • TPS08 (15)
  • TPS09 (14)
  • TPS10 (11)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (9)
  • TPS16 (12)
  • TPS17 (12)
  • TPS18 (11)
  • TPS19 (11)
  • TPS20 (13)
  • TPS21 (14)
  • TPS22 (11)
  • TPS23 (11)
  • TPS24 (12)
  • TPS25 (8)
  • TPS26 (16)
  • TPS27 (13)
  • TPS28 (5)
  • TPS29 (6)
  • TPS30 (12)
  • TPS31 (10)
  • TPS32 (12)
  • TPS33 (14)
  • TPS34 (15)
  • TPS35 (11)
  • TPS36 (11)
  • TPS37 (12)
  • TPS38 (12)
  • TPS39 (13)
  • TPS40 (10)
  • TPS41 (14)
  • TPS42 (15)
  • TPS43 (15)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (11)
  • TPS47 (14)
  • TPS48 (11)
  • TPS49 (12)
  • TPS50 (9)
  • TPS51 (8)
  • TPS52 (14)
  • TPS53 (12)
  • TPS54 (11)
  • TPS55 (13)
  • TPS56 (13)
  • TPS57 (5)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (12)
  • TPS61 (12)
  • TPS62 (13)
  • TPS63 (12)
  • TPS64 (15)
  • TPS65 (14)
  • TPS66 (13)
  • TPS67 (13)
  • TPS68 (11)
  • TPS69 (15)
  • TPS70 (13)
  • TPS71 (9)
  • TPS72 (13)
  • TPS73 (12)
  • TPS74 (10)
  • TPS75 (13)
  • TPS76 (10)
  • x TPS77 (7)
  • TPS78 (14)
  • TPS79 (13)
  • x TPS80 (11)
  • TPS81 (6)
  • TPS82 (12)
  • TPS83 (6)
  • TPS84 (11)
  • TPS85 (11)
  • TPS86 (13)
  • TPS87 (10)
  • TPS88 (9)
  • TPS89 (7)
  • TPS90 (5)
  • TPS91 (5)
18 results
Thumbnail

D3.357 - Revealing an Underlying Inborn Error of Immunity in Pediatric Granulomatous Disease: A Case of STAT1 Loss-of-Function–Associated Mendelian Susceptibility to Mycobacterial Disease after BCG Vaccination

Thumbnail

D3.361 - Pulmonary Embolism in a Patient with Hyper IgE (Job) Syndrome Associated with Genetic Thrombophilia: A Rare Case

Thumbnail

D3.362 - Ulcerative Colitis Developing in an Immunodeficiency Patient with CD19 Gene Mutation: A Case Report

Thumbnail

D3.363 - Systemic Lupus Erythematosus in a Patient with Hyper IgM Syndrome

Thumbnail

D3.366 - Experience With Berotralstat In The First Turkish Patients

Thumbnail

D3.367 - Clinical and immunological heterogeneity of 22q11.2 deletion syndrome in children from the Republic of Moldova

Thumbnail

D3.368 - Selective IgE Deficiency in Children: 10-Year Experience

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child

Thumbnail

D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD

Thumbnail

D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis

Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM